Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness

Table 1 Counts of product labels and all linked claims

Drug	Number of product labels	Number of VANDFRT		Number of DIKB inhibits/substrate		ClinicalTrials.gov	Published results
	for products containing	DDIs found for		of assertions with evidence		studies involving the	from ClinicalTrials.gov
	the drug	the drug		found for the drug		drug	studies involving the drug
		Significant	Critical	Evidence for	Evidence against
Antidepressants
Amitriptyline	57	16	8	0	0	1	1
Amoxapine	2	15	8	0	0	0	0
Bupropion	111	7	4	2	0	5	44
Citalopram	85	25	9	2*	4*	4	25
Desipramine	15	16	10	0	0	0	0
Doxepin	32	15	9	0	0	0	0
Duloxetine	17	26	8	3	4	4	4
Escitalopram	20	13	3	4*	5*	6	9
Fluoxetine	90	51	14	2	0	8	22
Imipramine	19	18	10	0	0	1	4
Mirtazapine	55	2	5	4	9	1	22
Nefazodone	5	39	20	3	6	0	0
Nortriptyline	29	16	11	0	0	3	24
Paroxetine	60	33	11	2	0	3	40
Selegiline	11	2	47	0	0	1	1
Sertraline	74	28	8	2	0	3	27
Tranylcypromine	2	3	61	0	0	3	71
Trazodone	38	8	10	1	0	2	2
Trimipramine	2	17	10	0	0	0	0
Venlafaxine	66	21	6	3	3	2	2
Antipsychotics
Aripiprazole	15	4	0	2	13	3	3
Clozapine	9	29	2	3	1	3	9
Olanzapine	42	0	1	1	0	5	13
Quetiapine	33	8	0	1	9	4	9
Risperidone	71	13	0	2	1	23	70
Ziprasidone	22	54	23	2*	9*	1	6
Sedative Hypnotics
Eszopiclone	11	7	0	1	7	1	1
Zaleplon	24	0	0	1	1	0	0
Zolpidem	85	0	0	2	0	0	0

^*Citalopram, escitalopram, and ziprasidone were each mapped to one claim for which there was both supporting and refuting evidence in the DIKB. Counts of product labels for each drug and claims that were linked to drug product labeling from three Linked Data drug information sources.

ISSN: 2041-1480